<DOC>
	<DOCNO>NCT00009763</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining monoclonal antibody therapy cyclosporine paclitaxel may effective treatment metastatic breast cancer . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody therapy , cyclosporine , paclitaxel treat patient recurrent refractory metastatic breast cancer .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy , Cyclosporine , Paclitaxel Treating Patients With Recurrent Refractory Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90 monoclonal antibody m170 combination cyclosporine paclitaxel patient recurrent refractory metastatic breast cancer . - Determine preliminary efficacy regimen patient . OUTLINE : This dose-escalation study yttrium Y 90 monoclonal antibody m170 ( Y90 MOAB m170 ) . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily 4 day prior apheresis continue daily maximum 5 day . A minimum 6 million CD34+ cells/kg must harvest . Patients receive oral cyclosporine every 12 hour day -3 25 . Patients receive unlabeled monoclonal antibody ( MOAB ) m170 IV follow tracer dose indium In 111 MOAB m170 IV day 0 . On day 7 , patient receive unlabeled MOAB m170 IV follow Y90 MOAB m170 IV . Patients cohorts 2-4 also receive paclitaxel IV 3 hour day 9 . If need , patient undergo autologous peripheral blood stem cell transplantation day 21 receive G-CSF SC daily blood count recover . Cohorts 3-6 patient receive escalate dos Y90 MOAB m170 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow monthly 3 month , every 3 month 1 year , every 6 month 1 year . PROJECTED ACCRUAL : A total 18-30 patient accrue study within 36 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic breast adenocarcinoma Residual recurrent disease firstline standard chemotherapy Clinical evidence metastatic disease Tumor cell positive m170 immunoreactivity HAMA titer negative Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Not specify Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine le 1.5 mg/dL Cardiovascular : LVEF least 50 % MUGA Pulmonary : FEV1 least 65 % predict FVC least 65 % predict DLCO least 60 % Other : No malignancy within past 5 year except nonmelanoma skin cancer adequately treat carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Chemotherapy Chemotherapy : See Disease Characteristics At least 1 prior chemotherapy regimen advance disease Prior highdose chemotherapy autologous stem cell transplantation allow give least 12 month prior study carmustine use At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior external beam radiotherapy No prior radiotherapy 25 % total skeleton Surgery : Not specify Other : No requirement oral anticoagulant ( lowdose warfarin central line thrombosis prophylaxis allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2003</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>